Built around GLP-1 life, not generic dieting MeAgain is shaped by people who deeply understand the GLP-1 journey: the appetite changes, side effects, dose changes, protein worries, hydration problems, body changes, and progress questions that show up in real life
Most common side effects were gastrointestinal, with 24.5% of participants in the phase 2 obesity trial discontinuing efinopegdutide 10 mg due to AE however when the same dose was used with gradual escalation at the MASLD trial (starting dose 2.4 mg for 4 weeks, then 5 mg for 4 weeks and then 10 mg), only 5.6% of participants discontinued the medication due to AE
Clinical trials have demonstrated that certain GLP-1 receptor agonists can: These benefits have changed how clinicians approach diabetes management, particularly for patients at high cardiovascular or renal risk
Starting early can help prevent sagging and maintain a balanced, youthful appearance
The peptide enhances tissue response to mechanical loading, potentially accelerating results from eccentric exercises and other PT interventions
Mood and motivation support: Stable blood sugar, improved sleep, GABA support, L-Tyrosine for neurotransmitter balance, and the psychological reinforcement of seeing the scale move all contribute to better mood and stronger motivation to continue
